CompaniesNeuren Pharmaceuticals
Neuren Pharmaceuticals logo

Neuren Pharmaceuticals

active
Camberwell, Australia
Founded 2001
Website
About

Small Molecules

Areas of Focus

Categories

Small Molecule PharmaceuticalAustralia
Team (11)
Clive Blower, BSc (Hons), PhD
Chief Operations Officer
Neuren Pharmaceuticals
team_member
Daryl Dekarske, M.P.H.
Chief Regulatory Officer
Neuren Pharmaceuticals
team_member
Dianne Angus
Non-Executive Director
Neuren Pharmaceuticals
team_member
DrJenny Harry,BSc (Hons), PhD
Non-Executive Director
Neuren Pharmaceuticals
team_member
Gerry Zhao, B Com (Hons Finance), B Law (Hons)
Chief Business Officer
Neuren Pharmaceuticals
team_member
Joe Basile, FIPA, FFA
Non-Executive Director
Neuren Pharmaceuticals
team_member
View all 11 team members →
Clinical Trials (16)
View all

Total Trials

16

As Lead Sponsor

16

As Collaborator

0

Total Enrollment

1,054

By Phase

PHASE2: 13PHASE1: 3

By Status

COMPLETED: 13WITHDRAWN: 1TERMINATED: 1SUSPENDED: 1
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT00805818
NCT00761228
Hover over trial bars to see details

Recent Trials

NCT05879614Lead Sponsor
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
PHASE2Withdrawn
Started: Sep 1, 2023 · Completed: Jun 30, 2025
NCT05025332Lead Sponsor
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
PHASE2Completed
28 participants
Started: Oct 14, 2022 · Completed: May 3, 2024
NCT05025241Lead Sponsor
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
PHASE2Completed
18 participants
Started: Aug 8, 2022 · Completed: Nov 17, 2023
NCT05011851Lead Sponsor
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
PHASE2Completed
17 participants
Started: Jul 12, 2022 · Completed: Jul 16, 2024
NCT04379869Lead Sponsor
To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers
PHASE1Completed
28 participants
Started: May 29, 2020 · Completed: Feb 11, 2021
View all 16 trials →
Locations (1)
Headquarters
Camberwell, Australia
Map

Loading map...